A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats

Brain

Volumn 136, Issue 2, 2013, Pages 412-432

  Nuber, Silke ^a,b   Harmuth, Florian ^b   Kohl, Zacharias ^c   Adame, Anthony ^a   Trejo, Margaritha ^a   Schönig, Kai ^d   Zimmermann, Frank ^d   Bauer, Claudia ^b   Casadei, Nicolas ^b   Giel, Christiane ^b   Calaminus, Carsten ^b   Pichler, Bernd J ^b   Jensen, Poul H ^e   Müller, Christian P ^c   Amato, Davide ^c   Kornhuber, Johannes ^c   Teismann, Peter ^f   Yamakado, Hodaka ^g,h   Takahashi, Ryosuke ^g,h   Winkler, Juergen ^c   Masliah, Eliezer ^a   Riess, Olaf ^b   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e AARHUS UNIVERSITY   (Denmark)

^f UNIVERSITY OF ABERDEEN   (United Kingdom)

^g KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

alpha synuclein; animal models; dopamine; Parkinson's disease; synapse function

Indexed keywords

ALPHA SYNUCLEIN; PROTEINASE K;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LOCOMOTION; MALE; MOTOR DYSFUNCTION; NERVOUS SYSTEM DEVELOPMENT; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEOTIDE SEQUENCE; OLFACTORY BULB; OLFACTORY DISCRIMINATION; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMELLING DISORDER; SYNAPSE;

EID: 84874335392     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aws358     Document Type: Article

References (123)

1. Amato D, Natesan S, Yavich L, Kapur S, Müller CP. Dynamic regulation of dopamine and serotonin responses to salient stimuli during chronic haloperidol treatment. Int J Neuropsychopharmacol 2011; 14: 1327-39.
2. Antonini A, Moresco RM, Gobbo C, De Notaris R, Panzacchi A, Barone P, et al. The status of dopamine nerve terminals in Parkinson's disease and essential tremor: a PET study with the tracer [11-C]FE-CIT. Neurol Sci 2001; 22: 47-8.
3. Baptista MJ, O'Farrell C, Daya S, Ahmad R, Miller DW, Hardy J, Farrer MJ, Cookson MR. Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines. J Neurochem 2003; 85: 957-68.
4. Beyer K, Lao JI, Carrato C, Mate JL, Ló pez D, Ferrer I, et al. Differential expression of alpha-synuclein isoforms in dementia with Lewy bodies. Neuropathol Appl Neurobiol 2004; 30: 601-7.
5. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
6. Brooks DJ. Imaging dopamine transporters in Parkinson's disease. Biomark Med 2010; 4: 651-60.
7. Cabin DE, Gispert-Sanchez S, Murphy D, Auburger G, Myers RR, Nussbaum RL. Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background. Neurobiol Aging 2005; 26: 25-35.
8. Calabrese F, Molteni R, Racagni G, Riva MA. Neuronal plasticity: a link between stress and mood disorders. Psychoneuroendocrinology 2009; 34: S208-16.
9. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004; 364: 1167-9.
10. Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 2010; 67: 715-25.
11. Chung CY, Koprich JB, Siddiqi H, Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci 2009; 29: 3365-73.
12. Culvenor JG, McLean CA, Cutt S, Campbell BC, Maher F, JäkäläP, et al. Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. Am J Pathol 1999; 155: 1173-81.
13. Daher JP, Ying M, Banerjee R, McDonald RS, Hahn MD, Yang L, et al. Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons. Mol Neurodegener 2009; 4: 34.
14. Dufty BM, Warner LR, Hou ST, Jiang SX, Gomez-Isla T, Leenhouts KM, et al. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am J Pathol 2007; 170: 1725-38.
15. Farrer M, Kachergus J, Forno L, Lincoln S, Wang DS, Hulihan M, et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 2004; 55: 174-9.
16. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114: 2283-301.
17. Finkelstein DI, Stanic D, Parish CL, Tomas D, Dickson K, Horne MK. Axonal sprouting following lesions of the rat substantia nigra. Neuroscience 2000; 97: 99-112.
18. Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, Levine MS, et al. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci 2004; 24: 9434-40.
19. Freichel C, Neumann M, Ballard T, Müller V, Woolley M, Ozmen L, et al. Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice. Neurobiol Aging 2007; 28: 1421-35.
20. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002; 34: 521-33.
21. Giasson BI, Murray IV, Trojanowski JQ, Lee VM. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem 2001; 276: 2380-6.
22. Gomez-Isla T, Irizarry MC, Mariash A, Cheung B, Soto O, Schrump S, et al. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiol Aging 2003; 24: 245-58.
23. Hasbi A, Fan T, Alijaniaram M, Nguyen T, Perreault ML, O'Dowd BF, et al. Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth. Proc Natl Acad Sci USA 2009; 106: 21377-82.
24. Herrera FE, Chesi A, Paleologou KE, Schmid A, Munoz A, Vendruscolo M, et al. Inhibition of alpha-synuclein fibrillization by dopamine is mediated by interactions with five C-terminal residues and with E83 in the NAC region. PLoS One 2008; 3: e3394.
25. Jaffar S, Counts SE, Ma SY, Dadko E, Gordon MN, Morgan D, et al. Neuropathology of mice carrying mutant APP(swe) and/or PS1(M146L) transgenes: alterations in the p75(NTR) cholinergic basal forebrain septohippocampal pathway. Exp Neurol 2001; 170: 227-43.
26. Jocham G, Lauber AC, Müller CP, Huston JP, De Souza Silva MA. Neurokinin 3 receptor activation potentiates the psychomotor and nucleus accumbens dopamine response to cocaine, but not its place conditioning effects. Eur J Neurosci 2007; 25: 2457-72.
27. Jowaed A, Schmitt I, Kaut O, Wüllner U. Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. J Neurosci 2010; 30: 6355-9.
28. Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, Schindzielorz A, et al. Subcellular localization of wild-type and Parkinson's diseaseassociated mutant alpha-synuclein in human and transgenic mouse brain. J Neurosci 2000; 20: 6365-73.
29. Kahle PJ, Neumann M, Ozmen L, Müller V, Odoy S, Okamoto N, et al. Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol 2001; 159: 2215-25.
30. Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 2002; 22: 2780-91.
31. Kohl Z, Winner B, Ubhi K, Rockenstein E, Mante M, Münch M, et al. Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model. Eur J Neurosci 2012; 35: 10-19.
32. Koprich JB, Johnston TH, Huot P, Reyes MG, Espinosa M, Brotchie JM. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein. PLoS One 2011; 6: e17698.
33. Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kösel N, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18: 106-8.
34. Krüger R, Vieira-Saecker AM, Kuhn W, Berg D, Müller T, Kühnl N, et al. Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype. Ann Neurol 1999; 45: 611-7.
35. Kuo YM, Li Z, Jiao Y, Gaborit N, Pani AK, Orrison BM, et al. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum Mol Genet 2010; 19: 1633-50.
36. Larsen KE, Schmitz Y, Troyer MD, Mosharov E, Dietrich P, Quazi AZ, et al. Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci 2006; 26: 11915-22.
37. Lazarini F, Lledo PM. Is adult neurogenesis essential for olfaction? Trends Neurosci 2011; 34: 20-30.
38. Lee BR, Kamitani T. Improved immunodetection of endogenous-synuclein. PLoS One 2011; 6: e23939.
39. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000; 47: 493-503.
40. Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, et al. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53-4 Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci USA 2002; 99: 8968-73.
41. Lelan F, Boyer C, Thinard R, Rémy S, Usal C, Tesson L, et al. effects of human alpha-synuclein A53T-A30P mutations on SVZ and local olfactory bulb cell proliferation in a Transgenic rat model of Parkinson disease. Parkinsons Dis 2011; 987084.
42. Lim Y, Kehm VM, Lee EB, Soper JH, Li C, Trojanowski JQ, et al.-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J Neurosci 2011; 31: 10076-87.
43. Lim Y, Kehm VM, Li C, Trojanowski JQ, Lee VM. Forebrain overexpression of alpha-synuclein leads to early postnatal hippocampal neuron loss and synaptic disruption. Exp Neurol 2010; 221: 86-97.
44. Lindersson E, Beedholm R, Højrup P, Moos T, Gai W, Hendil KB, et al. Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem 2004; 279: 12924-34.
45. Lo Bianco C, Schneider BL, Bauer M, Sajadi A, Brice A, Iwatsubo T, et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc Natl Acad Sci USA 2004; 101: 17510-5.
46. Lotharius J, Barg S, Wiekop P, Lundberg C, Raymon HK, Brundin P. Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J Biol Chem 2002; 277: 38884-94.
47. Lundblad M, Decressac M, Mattsson B, Björklund A. Impaired neurotransmission caused by overexpression of-synuclein in nigral dopamine neurons. Proc Natl Acad Sci USA 2012; 109: 3213-9.
48. Ma SY, RöyttäM, Rinne JO, Collan Y, Rinne UK. Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts. J Neurol Sci 1997; 151: 83-7.
49. Madete JK, Klein A, Dunnett SB, Holt CA. Three-dimensional motion analysis of postural adjustments during over-ground locomotion in a rat model of Parkinson's disease. Behav Brain Res 2011; 220: 119-25.
50. Magen I, Chesselet MF. Genetic mouse models of Parkinson's disease. The state of the art. Prog Brain Res 2010; 184: 53-87.
51. Mantoan L, Stefanova N, Egger KE, Jellinger KA, Poewe W, Wenning GK. Failure of caspase inhibition in the double-lesion rat model of striatonigral degeneration (multiple system atrophy). Acta Neuropathol 109: 191-7.
52. Maraganore DM, de Andrade M, Elbaz A, Farrer MJ, Ioannidis JP, Krüger R, et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. genetic epidemiology of Parkinson's disease (GEO-PD) consortium. JAMA 2006; 296: 661-70.
53. Marxreiter F, Nuber S, Kandasamy M, Klucken J, Aigner R, Burgmayer R, et al. Changes in adult olfactory bulb neurogenesis in mice expressing the A30P mutant form of alpha-synuclein. Eur J Neurosci 2009; 29: 879-90.
54. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005; 46: 857-68.
55. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000; 287: 1265-9.
56. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, et al. Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA 2001; 98: 12245-50.
57. Matsumoto L, Takuma H, Tamaoka A, Kurisaki H, Date H, Tsuji S, et al. CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease. PLoS One 2010; 5: e15522.
58. Matsuoka Y, Vila M, Lincoln S, McCormack A, Picciano M, LaFrancois J, et al. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol Dis 2001; 8: 535-539.
59. Miake H, Mizusawa H, Iwatsubo T, Hasegawa M. Biochemical characterization of the core structure of alpha-synuclein filaments. J Biol Chem 2002; 277: 19213-19.
60. Miller DW, Hague SM, Clarimon J, Baptista M, Gwinn-Hardy K, Cookson MR, et al. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 2004; 62: 1835-8.
61. Mishizen-Eberz AJ, Norris EH, Giasson BI, Hodara R, Ischiropoulos H, Lee VM, et al. Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. Biochemistry 2005; 44: 7818-29.
62. Muntané G, Ferrer I, Martinez-Vicente M.-synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience 2012; 200: 106-19.
63. Murphy DD, Rueter SM, Trojanowski JQ, Lee VM. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 2000; 20: 3214-20.
64. Murray IV, Giasson BI, Quinn SM, Koppaka V, Axelsen PH, Ischiropoulos H, et al. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 2003; 42: 8530-40.
65. Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, Lee CS, et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain 2009; 132: 2970-9.
66. Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, McKenzie J, et al. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain 2011; 134: 3290-8.
67. Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, Spooren W, et al. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha- synucleinopathies. J Clin Invest 2002; 110: 1429-39.
68. Neumann M, Müller V, Kretzschmar HA, Haass C, Kahle PJ. Regional distribution of proteinase K-resistant alpha-synuclein correlates with Lewy body disease stage. J Neuropathol Exp Neurol 2004; 63: 1225-35.
69. Nuber S, Petrasch-Parwez E, Arias-Carrió n O, Koch L, Kohl Z, Schneider J, et al. Olfactory neuron-specific expression of A30P alpha-synuclein exacerbates dopamine deficiency and hyperactivity in a novel conditional model of early Parkinson's disease stages. Neurobiol Dis 2011; 44: 192-204.
70. Nuber S, Petrasch-Parwez E, Winner B, Winkler J, von Hörsten S, Schmidt T, et al. Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. J Neurosci 2008; 28: 2471-84.
71. Ogawa S, Chan J, Gustafsson JA, Korach KS, Pfaff DW. Estrogen increases locomotor activity in mice through estrogen receptor alpha: specificity for the type of activity. Endocrinology 2003; 144: 230-9.
72. Oueslati A, Fournier M, Lashuel HA. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog Brain Res 2010; 183: 115-45.
73. Overk CR, Kelley CM, Mufson EJ. Brainstem Alzheimer's-like pathology in the triple transgenic mouse model of Alzheimer's disease. Neurobiol Dis 2009; 35: 415-25.
74. Paleologou KE, Kragh CL, Mann DM, Salem SA, Al-Shami R, Allsop D, Hassan AH, et al. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 2009; 132: 1093-101.
75. Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, Zigmond MJ. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci 2002; 22: 3090-9.
76. Plaas M, Karis A, Innos J, Rebane E, Baekelandt V, Vaarmann A, et al. Alpha-synuclein A30P point-mutation generates age-dependent nigrostriatal deficiency in mice. J Physiol Pharmacol 2008; 59: 205-16.
77. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-7.
78. Ponnusamy R, Nissim HA, Barad M. Systemic blockade of D2-like dopamine receptors facilitates extinction of conditioned fear in mice. Learn Mem 2005; 12: 399-406.
79. Prediger RD, Batista LC, Medeiros R, Pandolfo P, Florio JC, Takahashi RN. The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease. Exp Neurol 2006; 202: 391-403.
80. Prediger RD, Rial D, Medeiros R, Figueiredo CP, Doty RL, Takahashi RN. Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) rat model of Parkinson's disease. Ann N Y Acad Sci 2009; 1170: 629-36.
81. Pum M, Carey RJ, Huston JP, Müller CP. Role of medial prefrontal, entorhinal, and occipital 5-HT in cocaine-induced place preference and hyperlocomotion: evidence for multiple dissociations. Psychopharmacology 2008; 201: 391-403.
82. Ralph RJ, Caine SB. Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice. J Pharmacol Exp Ther 2005; 312: 733-41.
83. Ralph-Williams RJ, Lehmann-Masten V, Geyer MA. Dopamine D1 rather than D2 receptor agonists disrupt prepulse inhibition of startle in mice. Neuropsychopharmacology 2003; 28: 108-18.
84. Recchia A, Rota D, Debetto P, Peroni D, Guidolin D, Negro A, et al. Generation of a alpha-synuclein-based rat model of Parkinson's disease. Neurobiol Dis 2008; 30: 8-18.
85. Ribeiro MJ, Thobois S, Lohmann E, du Montcel ST, Lesage S, Pelissolo A, et al. A multitracer dopaminergic PET study of young-onset parkinsonian patients with and without parkin gene mutations. J Nucl Med 2009; 50: 1244-50.
86. Richfield EK, Thiruchelvam MJ, Cory-Slechta DA, Wuertzer C, Gainetdinov RR, Caron MG, et al. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp Neurol 2002; 175: 35-48.
87. Riederer P, Wuketich S. Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 1976; 38: 277-301.
88. Rieker C, Dev KK, Lehnhoff K, Barbieri S, Ksiazek I, Kauffmann S, et al. Neuropathology in mice expressing mouse alpha-synuclein. PLoS One 2011; 6: e24834.
89. Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, et al. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 2002; 68: 568-78.
90. Salmi P, Ahlenius S. Sedative effects of the dopamine D1 receptor agonist A 68930 on rat open-field behavior. Neuroreport 2000; 11: 1269-72.
91. Sanchez HL, Silva LB, Portiansky EL, Herenu CB, Goya RG, Zuccolilli GO. Dopaminergic mesencephalic systems and behavioral performance in very old rats. Neuroscience 2008; 154: 1598-606.
92. Seidel K, Schöls L, Nuber S, Petrasch-Parwez E, Gierga K, Wszolek Z, et al. First appraisal of brain pathology owing to A30P mutant alpha-synuclein. Ann Neurol 2010; 67: 684-9. Erratum in Ann Neurol 2010; 67: 841.
93. Sekine T, Kagaya H, Funayama M, Li Y, Yoshino H, Tomiyama H, et al. Clinical course of the first Asian family with Parkinsonism related to SNCA triplication. Mov Disord 2010; 25: 2871-75.
94. Sengoku R, Saito Y, Ikemura M, Hatsuta H, Sakiyama Y, Kanemaru K, et al. Incidence and extent of Lewy body-related alpha-synucleinopathy in aging human olfactory bulb. J Neuropathol Exp Neurol 2008; 267: 1072-83.
95. Sgadò P, Viaggi C, Pinna A, Marrone C, Vaglini F, Pontis S, et al. Behavioral, neurochemical, and electrophysiological changes in an early spontaneous mouse model of nigrostriatal degeneration. Neurotox Res 2011; 20: 170-81.
96. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003; 302: 841.
97. Smith MA, Makino S, Kvetnansky R, Post RM. Effects of stress on neurotrophic factor expression in the rat brain. Ann N Y Acad Sci 1995; 771: 234-9.
98. Sorwell KG, Wesson DW, Baum MJ. Sexually dimorphic enhancement by estradiol of male urinary odor detection thresholds in mice. Behav Neurosci 2008; 122: 788-93.
99. Sossi V, de la Fuente-Ferná ndez R, Schulzer M, Troiano AR, Ruth TJ, Stoessl AJ. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Ann Neurol 2007; 62: 468-74.
100. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. Alpha-Synuclein in filamentous inclusions of lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci USA 1998; 95: 6469-73.
101. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839-40.
102. Stanic D, Finkelstein DI, Bourke DW, Drago J, Horne MK. Timecourse of striatal re-innervation following lesions of dopaminergic SNpc neurons of the rat. Eur J Neurosci 2003; 18: 1175-88.
103. Steidl JV, Gomez-Isla T, Mariash A, Ashe KH, Boland LM. Altered short-term hippocampal synaptic plasticity in mutant alpha-synuclein transgenic mice. Neuroreport 2003; 14: 219-23.
104. Sugama S, Cho BP, Degiorgio LA, Shimizu Y, Kim SS, Kim YS, Shin DH, et al. Temporal and sequential analysis of microglia in the substantia nigra following medial forebrain bundle axotomy in rat. Neuroscience 2003; 116: 925-33.
105. Summavielle T, Magalhã es A, Castro-Vale I, de Sousa L, Tavares MA. Neonatal exposure to cocaine: altered dopamine levels in the amygdala and behavioral outcomes in the developing rat. Ann N Y Acad Sci 2002; 965: 515-21.
106. Taschenberger G, Garrido M, Tereshchenko Y, Bähr M, Zweckstetter M, Kügler S. Aggregation of-Synuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons. Acta Neuropathol 2012; 123: 671-83.
107. Thiel CM, Schwarting RK. Dopaminergic lateralisation in the forebrain: relations to behavioural asymmetries and anxiety in male Wistar rats. Neuropsychobiology 2001; 43: 192-9.
108. Thiruchelvam MJ, Powers JM, Cory-Slechta DA, Richfield EK. Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice. Eur J Neurosci 2004; 19: 845-54.
109. Tofaris GK, Garcia Reitböck P, Humby T, Lambourne SL, O'Connell M, Ghetti B, et al. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J Neurosci 2006; 26: 3942-50.
110. Trantham-Davidson H, Neely LC, Lavin A, Seamans JK. Mechanisms underlying differential D1 versus D2 dopamine receptor regulation of inhibition in prefrontal cortex. J Neurosci 2004; 24: 10652-9.
111. Ubeda-Bañ on I,Saiz-Sanchez D,de la Rosa-Prieto C,Argandoñ a-Palacios L,Garcia-Muñ ozguren S,et al. Alpha-synucleinopathy in the human olfactory system in Parkinson's disease: involvement of calcium-binding protein-and substance P-positive cells Acta Neuropathol 2010 119.723-735.
112. Ubhi K, Inglis C, Mante M, Patrick C, Adame A, Spencer B, et al. Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of-synucleinopathy. Exp Neurol 2012; 234: 405-16.
113. Ubhi K, Rockenstein E, Mante M, Inglis C, Adame A, Patrick C, et al. Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J Neurosci 2010; 5 (30): 6236-46.
114. Urakawa S, Hida H, Masuda T, Misumi S, Kim TS, Nishino H. Environmental enrichment brings a beneficial effect on beam walking and enhances the migration of doublecortin-positive cells following striatal lesions in rats. Neuroscience 2007; 144: 920-33.
115. Wakamatsu M, Ishii A, Iwata S, Sakagami J, Ukai Y, Ono M, et al. Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice. Neurobiol Aging 2008; 29: 574-85.
116. Wersinger C, Prou D, Vernier P, Sidhu A. Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J 2003; 17: 2151-3.
117. Wersinger C, Sidhu A. Disruption of the interaction of alpha-synuclein with microtubules enhances cell surface recruitment of the dopamine transporter. Biochemistry 2005; 44: 13612-24.
118. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci USA 2011; 108: 4194-9.
119. Winner B, Lie DC, Rockenstein E, Aigner R, Aigner L, Masliah E, et al. Human wild-type alpha-synuclein impairs neurogenesis. J Neuropathol Exp Neurol 2004; 63: 1155-66.
120. Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J Neurochem 2004; 91: 451-61.
121. Yamakado H, Moriwaki Y, Yamasaki N, Miyakawa T, Kurisu J, Uemura K, et al.-Synuclein BAC transgenic mice as a model for Parkinson's disease manifested decreased anxiety-like behavior and hyperlocomotion. Neurosci Res 2012; 73: 173-7.
122. Zarranz JJ, Alegre J, Gó mez-Esteban JC, Lezcano E, Ros R, Ampuero I. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55: 164-73.
123. Zhang X, Egeland M, Svenningsson P. Antidepressant-like properties of sarizotan in experimental Parkinsonism. Psychopharmacology (Berl) 2011; 218: 621-34.